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monocytes, despite CX3CR1s ubiquitous expression. We aimed to
characterize the expression of CX3CR1 on sub-populations of mono-
cytes in early and established RA and to ascertain the functional
consequences of the interaction of chemokine and receptor on
monocyte biology in RA
Methods: We recruited 83 subjects with early (21), established active
(46) or inactive RA (16) and 13 healthy controls as a comparator group.
Monocyte subsets (CD14þCD16- and CD14þCD16-) were defined
by flow cytometry and CX3CR1 surface expression was determined by
its Relative Fluorescent Intensity(RFI). Soluble FKN(sFKN) was
quantified in peripheral blood (PB) and synovial fluid (SF) by ELISA.
The effect of membrane-bound FKN (mbFKN) on osteoclast differen-
tiation of monocyte subsets was assessed in vitro. Serum from
subjects with the combination of elevated CD16þ monocytes and
increased sFKN were analysed using a multiplex cytokine array and
compared with controls.
Results: The percentage of circulating CD16þ monocytes was
increased in the active RA groups [early, mean (þ/-SEM) 24.22%
(3.9) and active RA, 21.99% (2.61] in comparison with inactive disease
12.9% (2.2), p¼0.04, and healthy controls 11.1% (0.89), p¼0.03.
Furthermore, individuals with increased sFKN and elevated CD16þ
monocytes had significantly more circulating Il1a,-1b,-2,-10 and TNFa
than controls.
Downregulation of CX3CR1 on the osteoclast progenitor CD16-
sub-population was restricted to active RA, p<0.005. Additionally,
CX3CR1 surface expression was down-regulated on CD16þ mono-
cytes in established RA but not in early arthritis, p¼0.004. Serum
sFKN was significantly higher in active RA, p¼0.02. CX3CR1 down-
regulation was replicated in vitro by co-incubation with sFKN. MbFKN
significantly enhanced the osteoclastogenesis of the CD16- monocyte
subset (p<0.0001) potentially mediated by a decrease in CX3CR1
surface expression.
Conclusions: These findings support the presence of a unique
monocyte phenotype in established RA. The downregulation of
CX3CR1 on osteoclast precursors is mediated by the interaction
with FKN. In addition the pro-osteoclastogenic effect of mbFKN
strongly supports that this chemokine partnership is critical to the
erosive process in RA.
Disclosure statement: The authors have declared no conflicts of
interest.
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Andrew Nesbitt1 and Gianluca Fossati1
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Background: Activities of the anti-TNFs, certolizumab pegol (CZP),
etanercept (ETA), infliximab (IFX) and adalimumab (ADA), have been
compared in a range of in vitro assays. CZP is the only licensed
PEGylated Fab’ anti-TNF; ETA is a fusion protein with an IgG1 Fc, and
IFX and ADA are both antibodies with an IgG1 Fc. Golimumab (GLM) is
a monoclonal IgG1 TNF inhibitor recently approved for a number of
indications; it is thus of interest to assess the in vitro activity of GLM.
In vitro assays previously used were neutralisation of TNF in the L929
bioassay, inhibition of LPS-driven cytokine production by monocytes,
induction of apoptosis in activated lymphocytes and monocytes, and
induction of neutrophil necrosis.
Methods: Neutralisation of human TNF was assessed in the L929
bioassay using a range of concentrations of the anti-TNFs and a fixed
concentration of TNF (100 pg/mL). Activity of the anti-TNFs at inhibiting
LPS-driven IL-1b secretion by monocytes was assessed by incubating
peripheral blood monocytes with various concentrations of the anti-
TNF for 1 hour (hr) and then washing the cells. LPS was added for
4 hrs, the supernatants collected and the IL-1b level measured by
ELISA. To assess induction of apoptosis, peripheral blood lympho-
cytes were activated for 2 days with 2g/mL CD3/CD28 and
monocytes with 300 U/mL IL-4 and GMCSF for 3 days. The effect of
the anti-TNFs on apoptosis was assessed by Annexin V staining using
flow cytometry 24 hrs later. The effect of the anti-TNFs on neutrophil
necrosis was determined by measuring myeloperoxidase release after
12 hrs. An isotype-matched control was used in all assays except the
L929 bioassay.
Results: IC90 neutralisation activity of the anti-TNFs in the L929
bioassay was 0.3 ng/mL for ETA, 4 ng/mL for GLM, 15 ng/mL for ADA,
and 20 ng/mL for IFX, compared with 2.5 ng/mL for CZP. CZP was the
most potent inhibitor of LPS-driven IL-1b secretion (IC50 0.1 ng/mL),
followed by GLM (20 ng/mL) and IFX (50 ng/mL). GLM, ADA, IFX and
ETA induced apoptosis of monocytes and lymphocytes to a similar
degree reaching a level of 23% and 40% at 100g/mL, respectively.
CZP caused no increase in apoptosis above the levels seen with the
isotype-matched control. In the neutrophil necrosis assay, ADA,IFX
and GLM caused 70% necrosis at 100g/mL, and ETA 48%. CZP
did not increase the level of necrosis above the level of the control.
Conclusions: Bioactivity of the IgG1 molecules GLM, IFX and ADA in
neutralising human TNF was inferior to that of CZP and ETA. CZP, the
only PEGylated anti-TNF, had a different profile to the other anti-TNFs
as it was the most potent at inhibiting LPS-driven IL-1b production by
monocytes, did not induce apoptosis of activated monocytes and
lymphocytes, and did not cause neutrophil necrosis. The clinical
relevance of these in vitro effects is unknown. Nevertheless, these
assays show interesting in vitro differences between the anti-TNFs.
Disclosure statement: G.F. and A.N. are employees of UCB.
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Background: Rheumatoid arthritis (RA) is a chronic inflammatory
disease in which chemokines have been shown to have an important
role. Chemokines are known to be inflammatory mediators and attract
leukocytes to sites of inflammation; this is achieved by binding to
glycosaminoglycan (GAG) chains on the luminal endothelial cell (EC)
surface and presentation to leukocyte chemokine receptors.
Methods: This study investigated the chemokine binding molecules
present in RA synovium and found that there were specific sulphated
heparan sulphate (HS) structures in situ that may be involved in
chemokine binding. CXCL8, an inflammatory chemokine that is known
to be angiogenic, was shown to induce the formation of microvilli on
ECs however, this was not just specific to CXCL8 since the same
effects were observed with CXCL10 (IP-10) and CCL5 (RANTES).
In vitro studies revealed colocalisation of CXCL8 and HS on the
endothelial microvilli. This suggests that the HS-CXCL8 interaction has
an important role in leukocyte transendothelial migration, since
removing HS caused a significant decrease in the number of
leukocytes undergoing transendothelial migration.
Results: Transmission electron microscopy imaging showed that
CXCL8-stimulated microvilli interacted with leukocytes prior to
transendothelial migration occurring, this again is suggestive that the
microvilli are involved in leukocyte transendothelial migration.
Mass spectrometry analysis of CXCL8-stimulated ECs showed
significant changes in cytoskeletal proteins, adhesion and extracellular
matrix proteins, and signal transduction proteins. This suggests that
CXCL8 binding to receptors on the EC surface causes an alteration in
Ras and Ca2þ signalling pathways, a reorganisation of the cytoskel-
eton and a disruption of the basement membrane, in order for the
microvilli to form
Conclusions: Overall, there appears to be an important function for
EC-microvilli and future targets of this could be of therapeutic
advantage to chronic inflammatory diseases such as RA.
Disclosure statement: The authors have declared no conflicts of
interest.
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AND IN SITU AUTOANTIBODY PRODUCTION IN
AUTOIMMUNE DIABETIC NOD MICE: CELLULAR AND
MOLECULAR CHARACTERIZATION OF TERTIARY LYMPHOID
STRUCTURES IN PANCREATIC ISLETS
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Background: A pivotal role for tertiary lymphoid structures (TLS) in
promoting antigen-specific humoral responses during chronic inflam-
mation is emerging in several autoimmune conditions, including
rheumatoid arthritis, Sjogren’s syndrome and autoimmune thyroiditis.
iii52 Tuesday 12 April 2011, 19:30–21:00 Poster Viewing 1
However, there is limited evidence on the cellular and molecular
mechanisms underlying TLS formation and their contribution to
autoimmunity in the pancreas during autoimmune insulitis.
Methods: Here we performed a detailed and comprehensive assess-
ment of the evolution of TLS during autoimmune insulitis in 126 female
NOD mice from 4 to 38 weeks of age.
Results: We demonstrated that during progression from peri- to intra-
insulitis in early diabetic mice, T and B cell infiltration follows a highly
regulated process with the formation of lymphoid aggregates
characterised by T/B cell segregation, follicular dendritic cells (FDC)
networks and differentiation of germinal center (GC) B cells. This
process is preceded by local up-regulation of lymphotoxins(Lt)a/b and
lymphoid chemokines (CKs) CXCL13 and CCL19 and is associated
with infiltration of B220/ IgDþ/CD23þ/CD21- follicular B cells ex-
pressing CXCR5. Despite a similar incidence of insulitis, late diabetic
mice displayed a significantly reduced incidence of fully organized TLS
and reduced levels of Lt/CKs. Upon development, TLS were fully
functional in supporting in situ autoreactive B cell differentiation, as
demonstrated by the expression of activation-induced cytidine
deaminase (AID), the enzyme required for Ig affinity maturation and
class-switching, and the presence of CD138þ plasmacells displaying
anti-insulin reactivity.
Conclusions: Overall, our work provides direct evidence that TLS
are of critical relevance in promoting autoimmunity and chronic
inflammation during autoimmune insulitis and diabetes in NOD mice.
Disclosure statement: The authors have declared no conflicts of
interest.
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Background: During cellular stress, the decrease in protein translation
caused by eIF2a phosphorylation reduces protein load in the endo-
plasmic reticulum (ER) which allows the cell a window of time to
instigate a program of gene expression known as the unfolded protein
response (UPR). To allow the recovery of protein translation, GADD34
is activated in a negative feedback loop which dephosphorylates eIF2a
and enables more efficient protein translation and recovery from
cellular stress. We have previously shown that ER stress signals are
induced following bacterial infection and that these signals synergise
with Toll-like -receptor (TLR) signals to enhance the expression of
cytokines such as IL-23. The aim of this study was to determine if TLR
signals have a reciprocal activity and modify the ER stress response
and in particular the expression of GADD34, the molecule involved in
translation recovery from ER stress.
Methods: Monocyte derived dendritic cells (mDC) were subjected to
ER stress using thapsigargin (TP) or tunicamycin (TM) in the presence
or absence of different pattern recognition receptor (PRR) agonists.
mDC were also infected with the obligate intracellular bacterium,
Chlamydia trachomatis (CT). The expression of GADD34 was analysed
by real time qPCR and immunoblotting. To determine which TLR
signalling pathways were involved in the upregulation of GADD34 we
manipulated TLR signalling pathways in THP-1 cells by the expression
of shRNA that targeted MyD88 expression.
Results: The expression of GADD34 mRNA and protein was induced
by the ER stress stimuli, tunicamycin but was significantly enhanced
by stimulation with LPS (TLR4), Curdlan (dectin 1) or peptidoglycan
(TLR2 and NOD2) agonists. Substantial upregulation of GADD34
expression was detected in mDC and THP-1 following infection with
CT. The upregulation of GADD34 induced by PRR agonists or CT
infection was reduced in THP-1 cells expressing MyD88 shRNA. Using
specific inhibitors for defined signalling pathways we identified that
upregulation of GADD34 was dependent on the activity of p38Map
kinase.
Conclusions: These data suggest that GADD34 upregulation is a
common feature of PRR responses when ER stress signals are
present. Furthermore intracellular bacterial infection is a potent signal
for GADD34 expression and that Myd88 dependent signals are
required for these responses.
These data show that the regulation of protein translation has not
only the potential to be modulated via ER stress but also via the
stimulation of PRR pathways. This may have significant implications
for the expression of pro-inflammatory or regulatory cytokines. We
hypothesize that changes in GADD34 expression induced by TLRs will
contribute significantly to the ability of myeloid cells to secrete pro-
inflammatory cytokines in response to bacterial infection.
Disclosure statement: The authors have declared no conflicts of
interest.
29. HUMAN (H161R) IL-17F MUTANT IS A DUAL
ANTAGONIST OF IL-17A AND IL-17F
Gayatri A. Mittal1, Rizgar A. Mageed1 and Yuti Chernajovsky1
1Bone and Joint Research Unit, William Harvey Research Institute,
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Background: The proinflammatory cytokine IL-17A and its closely
related isoform IL-17F play a key role in the pathogenesis of
rheumatoid arthritis (RA). IL-17A and IL-17F induce the secretion of
mediators of inflammation and growth factors such as TNF-alpha, IL-1,
IL-6, IL-8, matrix metalloproteases, GRO-alpha, MCP-1, PGE2 and
NO; inhibit cartilage synthesis and promote destruction of cartilage
and bone. In animal models of arthritis, administration of exogenous
IL-17A and IL-17F exacerbated arthritis while blockade of IL-17A
ameliorated the disease. In patients with RA, the levels of IL-17A and
IL-17F are increased in the synovium and the synovial fluid. Recent
phase I and II trials of neutralisation of IL-17A in RA using IL-17
monoclonal antibody have reported significant clinical improvement
and no notable side-effects.
A natural variant of IL-17F, (H161R) IL-17F mutant, resulting from
substitution of Histidine at amino acid position 161 by Arginine was
reported to be an antagonist of IL-17F [1]. Individuals having
homozygous alleles for this mutant are protected from asthma. In
in vitro studies, the mutant was unable to activate downstream
signaling pathways in bronchial epithelial cells (BEC). Further, it
competitively inhibited the induction of IL-8 secretion by the wild-
type IL-17F in BEC. Hypothesis: IL-17A and IL-17F genes share 55%
sequence homology, the proteins bind to the same hetero-receptor IL-
17R A/C and have overlapping biological functions. The striking
structural and functional similarities between the two isoforms of IL-17
point towards a strong possibility that in addition to IL-17F, the
(H161R) IL-17F mutant is also an inhibitor of IL-17A.
Methods: Human IL-17A and IL-17F were cloned into the expression
plasmid vector pcDNA3 at BamH1 and Xba1 sites. To create (H161R)
IL-17F mutant, the carboxy terminal end of IL-17F at BSPM and Xba1
sites was substituted by custom-ordered oligonucleotide that con-
tained the mutated base pair and cloned into the pcDNA3. The
constructs were expressed by transient transfection of 293T cells.
The expressed proteins were immunoprecipiated and shown to have
the expected molecular weight of 17.5 kDa by Western blotting.
Biological activities of human IL-17A and IL-17F were assessed by
measuring IL-17-induced production of IL-6 in HeLa cells by ELISA.
Competitive inhibition assays were carried out to determine the degree
of inhibition of IL-17A and IL-17F-induced secretion of IL-6 in HeLa
cells by addition of equal concentrations of the IL-17F mutant.
Results: IL-17F mutant competitively inhibited IL-17A- and IL-17F-
induced secretion of IL-6 in HeLa cells by 76% and 59%, respectively
as measured by ELISA.
Conclusions: Results of the study reveal for the first time that(H161R)
IL-17F mutant is an antagonist of both IL-17A and IL-17F.
Disclosure statement: Y.C., R.M. and G.M. have received research
grants from Barts and The London Charity and Arthritis Research UK.
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Background: Cryopyrin-associated periodic syndrome (CAPS) is a
spectrum of hereditary fever diseases including, familial cold auto-
inflammatory syndrome [FCAS]; Muckle-Wells syndrome [MWS];
neonatal-onset multisystem inflammatory disease/chronic infantile
neurological cutaneous and articular syndrome/ [NOMID/CINCA])
associated with mutations in NLRP3 causing overproduction of
interleukin-1b (IL-1b). Effect of selective and prolonged IL-1b blockade
with canakinumab, a fully human mAb, was evaluated in the largest
cohort of CAPS patients studied to date.
Methods: Canakinumab-naı¨ve or pretreated patients from earlier
studies received canakinumab s.c. 150 mg or 2 mg/kg (40 kg) every 8
weeks for up to 2 years. Primary objective was to assess the long-term
safety and tolerability of canakinumab in CAPS patients. Key assess-
ments included complete response (CR, for naı¨ve patients), response
maintenance, and percentage of patients requiring dose adjustments.
CR was defined as physician’s global assessment of disease activity
(PGDA) and skin assessmentminimal and normal CRP and/or SAA
values (<10 mg/L). Relapse was defined for patients with complete
response as serum CRP and/or SAA levels>30 mg/L and PGDA>
minimal or PGDA¼minimal plus skin assessment>minimal.
Results: This phase III, open-label study enrolled 166 (47 paediatric)
patients aged 3-91 years (30 FCAS; 103 MWS; 32 MWS/NOMID
[14 NOMID/CINCA]; one child without CAPS discontinued [protocol
violator]). 109 patients were canakinumab-naı¨ve and 57 were pre-
treated with canakinumab. 151 (91%) patients completed the study
and 15 patients discontinued (3 due to adverse events [AEs]). Median
treatment duration was 414 days (range 29-687 days) and the mean
number of injections/patient was 7.2. CR was achieved in 85/109
(78%) canakinumab-naı¨ve patients (79 achieved CR within 8 days, and
others later within 21 days). Of the 141 patients with relapse
assessment, 127 (90%) had no relapse, 14 (10%) relapsed and 23
incomplete responders later had improvement of disease symptoms.
Dose/dosing frequency adjustments were needed in 40 (24.1%)
patients (19.3% adults vs 36.2% children). In canakinumab-naı¨ve
patients median CRP/SAA levels normalized by Day 8 [2.5/4.9 mg/L
(at baseline 19.9/35.6 mg/L, respectively] and were maintained through
2-years in the entire cohort. Predominant AEs were infections (65%) of
mostly mild to moderate severity. Most frequent AEs were nasophar-
yngitis, headache and rhinitis. Serious AEs were reported in 18 (11%)
patients, mainly infections responsive to standard treatment. Injection-
site reactions were absent in 92% of patients and 8% reported mild to
moderate reactions.
Conclusions: Canakinumab 150 mg s.c. every 8 weeks provided rapid
improvement of symptoms and sustained remission in a large cohort
of CAPS patients across different severity phenotypes. Safety profile
supported the earlier data, reassuring good tolerability and safety of
canakinumab.
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31. IRF5 PROMOTES INFLAMMATORY MACROPHAGE
POLARIZATION AND TH1/TH17 RESPONSE
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Background: Genetic polymorphisms in the interferon regulatory
factor 5 (IRF5) gene, leading to expression of several unique isoforms
of IRF5 or increased expression of IRF5 mRNA, are associated with
a number of autoimmune diseases, including rheumatoid arthritis (RA),
systemic lupus erythematosis (SLE), Sjogren’s syndrome and athero-
sclerosis. The remarkable consistency of IRF5 detection in genome-
wide association studies of autoimmune diseases is likely to relate
to their common inflammatory origin. Many autoimmune diseases
are characterised by the predominant presence of Th1/Th17 cells as
well as macrophages. It has become increasingly clear that macro-
phages are dynamic and heterogeneous cells that can be divided into
specific, although overlapping, subsets according to their polarization
requirements, phenotype and function. Based on Th1/Th2 polarisation
concept they are now referred to as pro-inflammatory classical M1
(IL-12high, IL-23high, TNFhigh, IL-10low) macrophages and anti-
inflammatory M2 (IL-12low, IL-23low, TNFlow, IL-10high) macro-
phages. However, in contrast to T cell subsets, characterised by the
expression of master regulator transcription factors, e.g. FOXP3,
RORgammaT etc, the transcription factor(s) underlying macrophage
polarization remain largely unknown.
Methods: Enriched populations of human monocytes were obtained
from the blood of healthy donors and differentiated into M1 and M2
macrophages. Cytokine production (IL-12, IL-23, TNF, IL-1beta, IL-17,
IL-10) was measured by ELISA and RT-PCR. Mixed lymphocyte
reactions were performed to examine the effect of IRF5 expressing
macrophages on lymphocyte proliferation, fate and activation state.
Micro array analysis was used to define the IRF5-induced expression
profile on a genome-wide level. ChIP was used to investigate the
recruitment of IRF5 to specific target genes. The involvement of IRF5 in
macrophage polarization was also investigated in vivo by performing a
mouse model of M1 polarizing inflammation in wild-type and IRF5
knock-out mice.
Results: IRF5 directs transcriptional activation of the majority of
M1-specific cytokines (IL-12, IL-23, TNF), chemokines (RANTES) and
co-stimulatory molecules (CD40, CD86). It promotes T lymphocyte
proliferation, the development of Th1/Th17 lineages and plays a major
role in the plasticity of macrophages, from inflammatory to those that
mediate resolution of inflammation. Furthermore, IRF5 controls
macrophage plasticity by acting as a transcriptional repressor of IL-
10 and other selected M2-specific molecules.
Conclusions: Here we define IRF5 as the first major transcriptional
regulator of importance for the dichotomy between pro-inflammatory
M1 and anti-inflammatory M2 macrophages. The identification of such
a master regulator of macrophage phenotype and function has
ramifications for all inflammatory diseases characterised by excessive
type 1 cytokines and provides a potential new target for immune
intervention.
Disclosure statement: The authors have declared no conflicts of
interest.
32. 25-HYDROXYVITAMIN D3 CONVERSION BY DENDRITIC
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1School of Immunity and Infection, University of Birmingham,
Birmingham, United Kingdom
Background: Low vitamin D status is associated with an increased
risk of autoimmune diseases, including rheumatoid arthritis. Thus,
understanding how vitamin D modifies immune reactions holds
therapeutic potential. We have shown that 1,25(OH)2D3, the active
form of vitamin D, acts directly upon human CD4þ T cells, suppressing
inflammatory cytokines (IL-17, IL-21, IFN and IL-22) whilst enhancing
regulatory-markers (CTLA-4, CD25, FoxP3 and IL-10). However, the
short half-life of 1,25(OH)2D3 and its low serum level imply that local
conversion of 25(OH)D3, the major circulating form of vitamin D, by 1a-
hydroxylase (CYP27B1), is necessary for immune regulation in-vivo.
Thus, we have studied the effect of 25(OH)D3 upon T cell responses. In
view of the critical role of CTLA-4 in immune-regulation and its strong
sensitivity to 1,25(OH)2D3, we have also investigated CTLA-4 function
in vitamin D-modified immune responses. Lastly, in considering a use
for vitamin D in inflammatory arthritis treatment, we analysed its effects
upon T cells from synovitis patients.
Methods: CD4þCD25- T cells were purified from human peripheral
blood (PB) and stimulated with LPS-matured allogenic dendritic cells
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(DCs) plus antiCD3 or with antiCD3/CD28 beads in the presence and
absence of 25(OH)D3. FoxP3, CTLA-4 and cytokines were measured
by flow cytometry and CYP27B1 by qPCR. In function assays, CTLA-4
was blocked with antiCTLA-4 and T cell division monitored by CFSE.
DC expression of CD80 and CD86 was assessed by flow cytometry.
Synovitis patients were recruited from Birmingham City Hospital. Their
PB and synovial fluid (SF) mononuclear cells were stimulated with
antiCD3 in the presence and absence of 1,25(OH)2D3 and cytokines
examined by flow cytometry.
Results: Stimulation of T cells by DCs in the presence of 25(OH)D3 led
to strong suppression of IL-17 and IFN but up-regulation of CTLA-4
and CTLA-4þFoxP3þ frequencies. By contrast, in the absence of DCs,
25(OH)D3 caused modest CTLA-4 induction and IFN suppression
(P<0.05 for all). These differences corresponded with CYP27B1
levels, as maturation induced much higher CYP27B1 in DCs than
arose in T cells (P<0.05). CTLA-4 blockade overcame 1,25(OH)2D3-
mediated suppression of T cell division in DC stimulations and
prevented down-regulation of co-stimulatory CD80 and CD86 on
DCs. PB T cells from synovitis patients responded normally to
1,25(OH)2D3 with suppressed IL-17 and IFN (P<0.0001).
1,25(OH)2D3 also reduced SF IL-17 (P<0.05) but not IFN.
Conclusions: We have shown that DCs can efficiently convert
25(OH)D3 to drive 1,25(OH)2D3-modified T cell responses and that
up-regulation of CTLA-4 is mechanistically important in immune
suppression by vitamin D. Thus, 25(OH)D3 supplement could be
useful in the treatment of conditions such as RA. This is supported by
our finding that T cells from synovitis patients can respond to
1,25(OH)2D3.
Disclosure statement: The authors have declared no conflicts of
interest.
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33. EVALUATION OF THE FIRST BSR ULTRASOUND
ANATOMY TRAINING COURSE
Iain Goff1, David Coady1 and David Wright1
1City Hospitals Sunderland, Sunderland, United Kingdom
Background: The expansion of US availability has allowed increasing
numbers of rheumatologists to perform MSKUS in clinic. As yet there
is no formalized program of ultrasound learning or competency
assesment for rheumatologists. Detailed understanding of 3D ultra-
sound anatomy is recommended by European authors but very few UK
rheumatologists have recieved any formal anatomy training since
medical school.
Methods: The aim was to deliver a short anatomy training course in an
anatomy laboratory for rheumatologists tailored to the published BSR
ultrasound competency outcomes. The course was intended to be
learner centred, clinically meaningful and as recommended in current
anatomy teaching guidance the course would use a variety of learning
techniques in small groups including dissected prosections, ultra-
sound demonstrations on living models, radiological images and 3D
interactive software. This new course took place at Newcastle
University Anatomy Laboratory with 15 delegates in October 2010.
Results: In a specific questionaire survey of the 15 delegates (Likert
scale 1-5, not agree at all-very much agree), the aims and objectives of
the course were considered to have been acheived. AIMS: to help
understanding and interpretation of the human anatomy encountered
using US (4.5), facilitate progression through levels of US competency
(3.7). OBJECTIVES: identification of the relevant anatomical structures
using regional cadaveric anatomy (4), increase confidence in identify-
ing anatomical structures using USS (3.5), and identification of surface
anatomy of regional anatomical structures (3.9). The course methods
recieved high scores - learner centred (4.3), clinically meaningful (4.6),
and the tutors were considered to be experts in their field (4.8). In
qualitative feedback, 3D anatomy skills were self reported ‘‘seriously
deficient’’ prior to the course and opportunity to handle prosections
was ‘‘highly valued’’. There was some support for course attendance
counting towards a formal postgraduate certificate in US, but limited
interest among respondees in a formal anatomy assessment within the
course (2.5). This one day course allowed very limited time for US
practice which was a percieved deficiency (2.54).
Conclusions: A coordinated approach is needed to ensure US
competency among rheumatologists, and this short anatomy training
course with expert tutors (radiologists, anatomists and rheumatolo-
gists with US skills) acheived specific aims and objectives including
increased confidence in identifying anatomical structures using US,
though it is not known if the course improved anatomy skills and
knowledge.
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34. WHAT DO PEOPLE WITH PRIMARY SYSTEMIC
VASCULITIS WANT TO KNOW ABOUT THEIR ILLNESS?
Janice Mooney1, Fiona Poland1, Nicola Spalding1, David G.I. Scott2
and Richard Watts1
1University of East Anglia, Norwich, United Kingdom; 2Rheumatology
Department, Norfolk & Norwich Hospital, Norwich, United Kingdom
Background: The primary systemic vasculitides; Wegener’s granulo-
matosis (WG),Churg Strauss syndrome (CSS), Microscopic polyangiitis
(MPA) and Polyarteritis Nodosa (PAN) are a group of rare conditions.
Modern therapy has converted these diseases from ones with a
very poor outcome to chronic diseases, which relapse and remit.
Very little is known about the educational needs of this group of
people.
Methods: A postal questionnaire survey of the membership of the
Stuart Strange Trust (a national UK vasculitis support group).
Respondents were asked to rank using a 5-point scale (1¼ not
important to 5¼ extremely important) the importance of providing
accurate information using the following categories: disease, medica-
tion and side effects, disease management, investigations and tests,
psychosocial care, and the preferred method of educational delivery.
Data was collected on who provided information at diagnosis
Results: 1000 questionnaires were distributed, 397 returned, 63
excluded not PSV, 40 returned not known at the address. 329
responses were available for analysis. Diagnosis WG 255, CSS 46,
PAN 15, MPA 13. 65% of respondents were male, median age 63
years (interquartile range 52-70), median disease duration 5 years
(interquartile range 4-6y). Only 41% of people received information at
diagnosis. Of these, the majority of information was provided by a
doctor 71%, other 18.5%, relative 5.7% and a nurse 4.8%.
Respondents ranked information on diagnosis, prognosis, results of
tests, treatments and side effects of medication as extremely import-
ant. Lifestyle issues were very important. Surprisingly information on
patient support groups and psychosocial care was viewed as less
important. There were no real differences in information needs
between the sexes and disease duration. Individuals preferred to be
told by a doctor that they had vasculitis and for this to be supported
with an information leaflet about their particular disease
Conclusions: This study highlighted that people with PSV required a
significant amount of information concerning their disease, treatment
regimes and side effects and the results of investigations and tests.
Individuals preferred to receive this information from a doctor.
However a significant number of people did not receive any informa-
tion. These individuals should be treated like other chronic illnesses
where patient education is a fundamental part of patient care.
Education programmes for PSV should be developed to empower
patients to become active partners in the management of their
condition.
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35. ADHERENCE TO TREATMENT OF THE ELDERLY
PATIENTS WITH INFLAMMATORY ARTHRITIS AT THE
RHEUMATOLOGY UNIT
Doris Aquilina1
1Rheumatology, Mater Dei Hospital, Msida, Malta
Background: For optimal health recovery, adherence to medication is
very important [1]. According to dherence to treatment is the behaviour
of how an individual takes his medication [2]. Adherence or compli-
ance can be used simultaneously. Salzman (1995) [3], estimated that
non-compliance in the elderly can vary from 40% to as much as 75%.
There can be three forms of non-compliance: overuse and abuse,
forgetfulness and changing of doses and schedules.
Methods: This was a quantitative study of a sample population of 50
patients aged over 60 years. These patients were assessed at the
outpatient rheumatology clinic in mater dei hospital in Malta. The aim
of the study was to assess adherence to medication in the elderly
population over the age of 60 who suffer from an inflammatory arthritis
and who are on treatment. Patients could be on one drug or double or
triple therapy. A validated questionnaire was used to assess the
patient’s adherence to their prescribed medication. The questionnaire
was used before and one month after the counselling on increasing
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